



MaxCyte to Present at BIO CEO & Investor Conf

February 5, 2020 12:00 PM EST

Released : February 05, 2020 07:00

RNS Number : 9797B
MaxCyte, Inc.
05 February 2020

FOR IMMEDIATE RELEASE

MaxCyte's CEO to Present Update on Life Sciences Business & First-in-class CARMA™ Cellular Therapies at BIO CEO & Investor Conference in New York

Gaithersburg, Maryland - 5 February 2020 - MaxCyte, the global cell-based therapies and life sciences company, announces its planned participation at the BIO CEO & Investor Conference at the New York Marriott Marquis. CEO & President Doug Doerfler will present Monday, 10 February at 2:30 p.m. ET (Odets Room) on how MaxCyte is driving the development of the next generation of cell-based therapies through its ExPERT™ instrument family, supporting its Life Sciences Business, and with its proprietary CARMA platform.

The ExPERT instrument family represents the next generation of the industry's leading, clinically validated, electroporation technology for complex and scalable cellular engineering. By delivering high transfection efficiency with enhanced functionality, the ExPERT platform delivers the high-end performance essential to enabling the next wave of biological and cellular therapeutics and provides a single discovery and development platform from concept to clinical development to commercialization. In 2019, the Company signed five clinical/commercial licenses with partners including Kite (Gilead), Editas Medicine, Vor Biopharma and KSQ Therapeutics, and now has more than 100 cell therapy programmes under license of which more than 70 are licensed for clinical use.

CARMA Cellular Therapies is developing its novel and proprietary technology for non-viral, human messenger RNA (mRNA)-based, chimeric antigen receptor (CAR) or T-cell receptor (TCR) redirected immune cell therapies for solid cancer and offers the potential for a safer cell therapy, as a result of transient expression of receptor(s) and a non-viral delivery approach. MaxCyte recently established its CARMA program as a wholly owned subsidiary to facilitate independent investment and new partnerships to advance the CARMA platform.

For a meeting with MaxCyte's CEO at the conference please contact Sheila Tiffany at sheilat@maxcyte.com.

About MaxCyte

MaxCyte is a clinical-stage global cell-based therapies and life sciences company applying its proprietary cell engineering platform to deliver the advances of cell-based medicine to patients with high unmet medical needs. Through its life sciences business, MaxCyte leverages its Flow Electroporation Technology to enable its biopharmaceutical partners to advance the development of innovative medicines, particularly in cell therapy. MaxCyte has placed its technology worldwide, including with all of the top ten global biopharmaceutical companies. The Company now has more than 100 partnered programme licenses in cell therapy with more than

70 licensed for clinical use. The Company has now signed eight clinical/commercial licenses with leading cell therapy developers and the potential pre-commercial milestones from these relationships now exceeds \$650 million. With its robust delivery technology platform, MaxCyte helps its partners to unlock the full potential of their products. MaxCyte is also developing novel CARMA therapies, with its first drug candidate in a Phase I clinical trial. CARMA is MaxCyte's mRNA-based proprietary therapeutic platform for autologous cell therapy for the treatment of solid cancers. MaxCyte has established CARMA as a wholly owned subsidiary to facilitate independent investment and new partnerships to advance the CARMA platform. For more information, visit www.maxcyte.com.

For further information, please contact:

MaxCyte Inc.

Doug Doerfler, Chief Executive Officer
Ron Holtz, Chief Financial Officer

+1 301 944 1660

Financial PR Adviser

Consilium Strategic Communications

Mary-Jane Elliott
Chris Welsh
Sukaina Virji

+44 (0)203 709 5700

maxcyte@consilium-comms.com

US Media Relations

Jamie Lacey-Moreira

+1 410 299 3310

jamielacey@presscommpr.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

NRAUPUBUPUPPPC